Core Viewpoint - Vertex Pharmaceuticals is experiencing mixed performance in the stock market, with a slight increase in share price but a decline over the past month, indicating potential challenges ahead [1][2]. Financial Performance - The upcoming earnings report on November 4, 2024, is expected to show an EPS of $4.11, reflecting a growth of 0.74% year-over-year, and revenue is projected at $2.68 billion, up 7.83% from the previous year [2]. - For the full year, earnings are projected at $0.05 per share, a significant decline of 99.67%, while revenue is expected to reach $10.74 billion, an increase of 8.84% compared to the prior year [3]. Analyst Projections - Recent shifts in analyst projections are crucial for understanding the company's near-term business trends, with positive revisions indicating a favorable outlook on business health and profitability [4]. - The Zacks Rank system currently rates Vertex Pharmaceuticals as 5 (Strong Sell), reflecting a stagnant EPS estimate over the past month [6]. Valuation Metrics - Vertex Pharmaceuticals has a Forward P/E ratio of 10389.82, significantly higher than the industry average of 22.58, indicating a premium valuation [7]. - The company also has a PEG ratio of 831.19, compared to the industry average of 2.28, suggesting that the stock may be overvalued relative to its expected earnings growth [8]. Industry Context - The Medical - Biomedical and Genetics industry, to which Vertex Pharmaceuticals belongs, has a Zacks Industry Rank of 86, placing it in the top 35% of over 250 industries, indicating overall strength in this sector [8][9].

Vertex Pharmaceuticals (VRTX) closed at $465.08 in the latest trading session, marking a +0.48% move from the prior day. This move outpaced the S&P 500's daily gain of 0.42%. Meanwhile, the Dow experienced a rise of 0.04%, and the technology-dominated Nasdaq saw an increase of 0.38%. The drugmaker's stock has dropped by 6.66% in the past month, falling short of the Medical sector's loss of 2.49% and the S&P 500's gain of 2.06%. The upcoming earnings release of Vertex Pharmaceuticals will be of great interes ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Vertex Pharmaceuticals (VRTX) . Vertex currently has an average ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Cantor Global Healthcare Conference September 17, 2024 9:10 AM ET Company Participants Susie Lisa - SVP, IR Manisha Pai - Executive Director, IR Conference Call Participants Olivia Brayer - Cantor Fitzgerald Olivia Brayer Joining us this morning at our Cantor Global Healthcare Conference. Really excited to have another year of it. My name is Olivia Brayer. I'm a senior Biotech Analyst here at Cantor. And we're really excited to have the Vertex IR team with u ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this drugmaker have returned +1.4% over the past month versus the Zacks S&P 500 composite's +4.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Vertex belongs, has gained 3.7% over this period. Now the key question is: Where could the stock be headed in ...

Vertex Pharmaceuticals Incorporated (VRTX) reported second-quarter 2024 results on Aug 1. Adjusted loss per share of $12.83 was wider than the Zacks Consensus Estimate of a loss of $11.50. The significant loss in the quarter was due to costs related to the $4.9 billion acquisition of Alpine Immune Sciences closed in May. Revenues of $2.65 billion were in line with the Zacks Consensus Estimate. Total revenues rose 6% year over year, primarily driven by higher sales of its cystic fibrosis (CF) drug Trikafta/K ...

Core Insights - Vertex Pharmaceuticals reported $2.65 billion in revenue for Q2 2024, a year-over-year increase of 6.1% [1] - The company experienced an EPS of -$12.83, a significant decline from $3.89 a year ago, with an EPS surprise of -11.57% [1][2] - The reported revenue was in line with the Zacks Consensus Estimate, showing a slight surprise of -0.08% [1] Revenue Breakdown - Geographic Revenues in the United States reached $1.61 billion, exceeding the estimated $1.59 billion, reflecting a +7.1% change year-over-year [3] - Geographic Revenues outside the United States were $1.03 billion, matching the analyst estimate and showing a +4.7% change from the previous year [4] - Revenues from the product Trikafta/Kaftrio totaled $2.45 billion, aligning with the seven-analyst average estimate and representing a +9.3% year-over-year increase [5] - Revenues from other CF products amounted to $196.40 million, surpassing the two-analyst average estimate of $179.54 million [6] Stock Performance - Vertex shares have returned +7.6% over the past month, contrasting with the Zacks S&P 500 composite's -0.4% change [6] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [6]

Vertex Pharmaceuticals Incorporated (VRTX) reported second-quarter 2024 adjusted loss per share of $12.83, which was wider than the Zacks Consensus Estimate of a loss of $11.50. In the year-ago quarter, Vertex recorded adjusted earnings of $3.89 per share. The significant loss in the quarter was due to costs related to the $4.9 billion acquisition of Alpine Immune Sciences, which was closed in May. The company reported total revenues of $2.65 billion, comprising cystic fibrosis (CF) product revenues. The fi ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Vertex Pharmaceuticals (VRTX) . Vertex currently has an average ...

Vertex Pharmaceuticals (VRTX) came out with a quarterly loss of $12.83 per share versus the Zacks Consensus Estimate of a loss of $11.50. This compares to earnings of $3.89 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -11.57%. A quarter ago, it was expected that this drugmaker would post earnings of $4.10 per share when it actually produced earnings of $4.76, delivering a surprise of 16.10%. Over the last four quarters, th ...